Thermo Fisher Scientific (TMO) : Bradley Foster Sargent Incct reduced its stake in Thermo Fisher Scientific by 23.65% during the most recent quarter end. The investment management company now holds a total of 218,944 shares of Thermo Fisher Scientific which is valued at $32.4 Million after selling 67,831 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on May 11, 2016.Thermo Fisher Scientific makes up approximately 1.51% of Bradley Foster Sargent Incct’s portfolio.
Other Hedge Funds, Including , Folger Nolan Fleming Douglas Capital Management Inc reduced its stake in TMO by selling 50 shares or 2.75% in the most recent quarter. The Hedge Fund company now holds 1,770 shares of TMO which is valued at $261,765. Thermo Fisher Scientific makes up approx 0.05% of Folger Nolan Fleming Douglas Capital Management Inc’s portfolio. Pictet North America Advisors Sa sold out all of its stake in TMO during the most recent quarter. The investment firm sold 1,985 shares of TMO which is valued $293,562.Ibm Retirement Fund reduced its stake in TMO by selling 44,845 shares or 46.33% in the most recent quarter. The Hedge Fund company now holds 51,947 shares of TMO which is valued at $7.7 Million. Thermo Fisher Scientific makes up approx 0.30% of Ibm Retirement Fund’s portfolio.Welch Forbes boosted its stake in TMO in the latest quarter, The investment management firm added 262 additional shares and now holds a total of 11,603 shares of Thermo Fisher Scientific which is valued at $1.7 Million. Thermo Fisher Scientific makes up approx 0.05% of Welch Forbes’s portfolio.
Thermo Fisher Scientific opened for trading at $147.9 and hit $150.43 on the upside on Monday, eventually ending the session at $150.24, with a gain of 1.59% or 2.35 points. The heightened volatility saw the trading volume jump to 14,73,044 shares. Company has a market cap of $59,121 M.
On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on May 3, 2016 to “Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $160 .Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.